GlassScriptPhysician profile
Cody Paul Carter
NPI 1174012132
$12,260.61
in general payments reported to CMS, 2019-2025
24 companies · $7,833 in 2025
The $7,833 reported for 2025 was more than what 87% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $268 · 2021: $239 · 2022: $1,304 · 2023: $1,744 · 2024: $758 · 2025: $7,833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,612 · Grant: $4,000 · Travel and Lodging: $1,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,612.42 |
| Grant | $4,000.00 |
| Travel and Lodging | $1,722.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,019.89 | 2023-2025 | Linq II |
| Boston Scientific Corporation | $2,352.27 | 2022-2025 | General - Vascular Access, Watchman Flx, Watchman Access System |
| Abbott Laboratories | $2,325.21 | 2022-2025 | Optis, Thoratec Heartmate 3 Lvas Implant Kit |
| Astrazeneca Pharmaceuticals LP | $738.59 | 2019-2023 | Farxiga, Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $481.38 | 2022-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $471.58 | 2023-2025 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $308.07 | 2022-2024 | Xarelto |
| Abiomed | $305.56 | 2023-2025 | Impella |
| Zoll Circulation INC | $195.00 | 2022-2023 | Downstream Cartridge, Catheter, Therox Ds2 Console |
| Inari Medical, INC. | $154.25 | 2020 | |
| Esperion Therapeutics, INC. | $126.17 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.99 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.85 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.66 | 2023 | Jardiance |
| Amgen INC. | $114.09 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $113.59 | 2020 | |
| Teleflex LLC | $36.80 | 2024-2025 | Supercross, Guideliner |
| E.R. Squibb & Sons, L.L.C. | $33.56 | 2022-2023 | Camzyos |
| Cardiva Medical, INC. | $27.47 | 2025 | Cardiva Vascade 5f Vcs |
| Heartflow, INC. | $21.14 | 2025 | |
| Lantheus Medical Imaging, INC. | $18.76 | 2024 | |
| Cordis US Corp. | $18.30 | 2023 | Rain Sheath Transradial |
| Novo Nordisk INC | $18.08 | 2023 | Ozempic |
| Biosense Webster, INC. | $16.35 | 2024 | Carto 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.